37 results
To provide clinical management and, if required, treatment to subjects who at their concluding HPV-015 study visit displayed normal cervical cytology but tested positive for oncogenic HPV infection or who were pregnant at their concluding visit of…
To determine the efficacy of 3 different Hepatitis B vaccines (HBVAXPRO 40 micrograms, Fendrix and Twinrix) in Hepatitis B vaccine non-responders (ant-HBsAg < 10 IU/L) after one (standard) series of Hepatitis B vaccination with HBVAXPRO-10…
To evaluate the safety, tolerability and immunogenicity of a Twincer®-administered dry powder influenza vaccine in healthy adults.
To investigate the long term (ten years) protective immune response to fractional yellow fever vaccination (1/5th of the standard dose, injected intradermally), compared to the standard subcutaneous vaccination
Primary Objective: To determine the height and duration of viremia, the seroconversion rate and the level of neutralising antibodies in relation to - the actual number of CD4 positive cells- the nadir of CD4 positive cells- the duration of CD4 count…
This study is designed to evaluate the immunogenicity and tolerability of V503 in young men, 16 to 26 years of age, in comparison to GARDASIL® in young men, 16 to 26 years of age. The safety and immunogenicity data will be used to bridge GARDASIL®…
1. To reduce the time required for pre-exposure rabies vaccination of military personnel2. To reduce costs of pre-exposure rabies vaccination of military personnel 3. To obtain a non-inferior immune response to a shortened, low-dosed scheme compared…
To study the immunogenicity and safety of adjuvanrt hepatitis B vaccin (Fendrix) compared to double-dosage of Engerix vaccination in HIV infected patients, previously failing HBV vaccinations.
To evaluate the effect of chemotherapy on the serological and cellular immune response to influenza virus vaccination in patients with breast or colorectal cancer in order to establisch the optimal timing of vaccination during treatment with…
To assess the safety, reactogenicity, and tolerability of increasing GEM intranasal doses (1.25 mg, 2.5 mg and 5.0 mg) and intramuscular doses (0.05, 0.1, 0.2 mg) of the GEM adjuvant, each administration containing as well a standard 2010/2011 Flu…
- To develop evidence-based and theory-guided target group specific interventions to improve the SRH of two specific groups of PLHIV, MSM and migrants, with particular emphasis on reduction of HIV transmission behaviour.- To test the effectiveness…
To compare: - the rate of local and systemic adverse events- height and duration of antibody presence using the plaque reduction neutralization test; - The number of yellow fever specific CD8+ T cells in peripheral blood mononuclear cells (PBMCs);…
* To demonstrate efficacy of the candidate vaccine in the prevention of (1) persistent infection (6-month definition) with HPV-16 or HPV-18 (by polymerase chain reaction [PCR]) and/or (2) histopathologically-confirmed CIN1+ associated with HPV-16 or…
To investigate what the ideal moment to vaccinate would be, early (after 2-6 months) or late (after 9-12 months) after cessation of rituximab. Secondly to study the immune-response to vaccination with influenza virus vaccine after treatment with…
To study if there is a role for prophylactic VZV vaccination prior to transplantation to boost the patients B- and T-cell repertoire and thereby reducing the incidence and morbidity associated with herpes zoster.
Primary objectiveSafety assessment of the MVA-H5-sfMR vaccine in humans. Study subjects will undergo physical examinations performed before and on fixed time points during the study. Clinical chemistry is performed on the blood samples that are…
·To compare the serological response to influenza vaccination in mamma carcinoma patients treated with FEC-containing, triweekly regimens at day 4 ( +/- 1 day) of the chemotherapy cyclus with the response to vaccination in otherwise healthy patients…
Characterization of T cell responses in young children after influenza infection
Characterization of the effects of ageing on the innate immune response against influenza.
Primary objectivesImmunogenicityTo demonstrate that a second dose of ZOSTAVAX® elicits higher varicella-zoster virus (VZV) antibody titres than a first dose of ZOSTAVAX® whether given as a 0-1 month schedule or as a 0-3 month schedule in subjects…